用于磁共振成像的可溶性肝胆造影剂。 - Suppr

Suppr

超能文献

Soluble-type hepatobiliary contrast agents for MR imaging.

作者信息

de Haën C, Gozzini L

机构信息

Research and Development Division, Bracco SpA, Milan, Italy.

出版信息

J Magn Reson Imaging. 1993 Jan-Feb;3(1):179-86. doi: 10.1002/jmri.1880030130.

DOI:10.1002/jmri.1880030130

PMID:8428085

Abstract

摘要

相似文献

Soluble-type hepatobiliary contrast agents for MR imaging.

J Magn Reson Imaging. 1993 Jan-Feb;3(1):179-86. doi: 10.1002/jmri.1880030130.

[Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].

Bildgebung. 1992 Dec;59(4):195-9.

[Magnetic resonance imaging of the liver: what kind of contrast agents?].

Radiol Med. 2001 Sep;102(3):109-21.

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Eur Radiol. 2004 Apr;14(4):559-78. doi: 10.1007/s00330-004-2236-1. Epub 2004 Feb 25.

Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.

Radiographics. 2009 Oct;29(6):1725-48. doi: 10.1148/rg.296095515.

Mechanisms of action of liver contrast agents: impact for clinical use.

J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. doi: 10.1097/00004728-199911001-00007.

[Status and development of new clinical contrast media for MR diagnosis of liver diseases].

Radiologe. 1992 May;32(5):225-31.

Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents.

J Magn Reson Imaging. 1994 May-Jun;4(3):337-42. doi: 10.1002/jmri.1880040319.

New contrast agents for imaging the liver.

Magn Reson Imaging Clin N Am. 2001 Nov;9(4):745-66, vi.

Contrast-enhanced MR imaging of the liver.

J Magn Reson Imaging. 1994 May-Jun;4(3):281-9. doi: 10.1002/jmri.1880040311.

引用本文的文献

Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.

Korean J Radiol. 2010 Jul-Aug;11(4):433-40. doi: 10.3348/kjr.2010.11.4.433. Epub 2010 Jun 21.

Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.

Radiat Oncol. 2010 May 27;5:44. doi: 10.1186/1748-717X-5-44.

[Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].

Radiologe. 2004 Dec;44(12):1185-91. doi: 10.1007/s00117-004-1134-5.

[Contrast agents in MRT. Substance, effects, pharmacology and validity].

Radiologe. 2004 Mar;44(3):273-83. doi: 10.1007/s00117-004-1026-8.

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Eur Radiol. 2004 Apr;14(4):559-78. doi: 10.1007/s00330-004-2236-1. Epub 2004 Feb 25.

Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Korean J Radiol. 2001 Oct-Dec;2(4):210-5. doi: 10.3348/kjr.2001.2.4.210.

Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI.

Magn Reson Med. 1997 Mar;37(3):448-56. doi: 10.1002/mrm.1910370324.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Soluble-type hepatobiliary contrast agents for MR imaging.

作者信息

de Haën C, Gozzini L

机构信息

Research and Development Division, Bracco SpA, Milan, Italy.

出版信息

J Magn Reson Imaging. 1993 Jan-Feb;3(1):179-86. doi: 10.1002/jmri.1880030130.

DOI:10.1002/jmri.1880030130

PMID:8428085

Abstract

摘要

相似文献

Soluble-type hepatobiliary contrast agents for MR imaging.

J Magn Reson Imaging. 1993 Jan-Feb;3(1):179-86. doi: 10.1002/jmri.1880030130.

[Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].

Bildgebung. 1992 Dec;59(4):195-9.

[Magnetic resonance imaging of the liver: what kind of contrast agents?].

Radiol Med. 2001 Sep;102(3):109-21.

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Eur Radiol. 2004 Apr;14(4):559-78. doi: 10.1007/s00330-004-2236-1. Epub 2004 Feb 25.

Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.

Radiographics. 2009 Oct;29(6):1725-48. doi: 10.1148/rg.296095515.

Mechanisms of action of liver contrast agents: impact for clinical use.

J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. doi: 10.1097/00004728-199911001-00007.

[Status and development of new clinical contrast media for MR diagnosis of liver diseases].

Radiologe. 1992 May;32(5):225-31.

Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents.

J Magn Reson Imaging. 1994 May-Jun;4(3):337-42. doi: 10.1002/jmri.1880040319.

New contrast agents for imaging the liver.

Magn Reson Imaging Clin N Am. 2001 Nov;9(4):745-66, vi.

Contrast-enhanced MR imaging of the liver.

J Magn Reson Imaging. 1994 May-Jun;4(3):281-9. doi: 10.1002/jmri.1880040311.

引用本文的文献

Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.

Korean J Radiol. 2010 Jul-Aug;11(4):433-40. doi: 10.3348/kjr.2010.11.4.433. Epub 2010 Jun 21.

Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.

Radiat Oncol. 2010 May 27;5:44. doi: 10.1186/1748-717X-5-44.

[Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].

Radiologe. 2004 Dec;44(12):1185-91. doi: 10.1007/s00117-004-1134-5.

[Contrast agents in MRT. Substance, effects, pharmacology and validity].

Radiologe. 2004 Mar;44(3):273-83. doi: 10.1007/s00117-004-1026-8.

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Eur Radiol. 2004 Apr;14(4):559-78. doi: 10.1007/s00330-004-2236-1. Epub 2004 Feb 25.

Korean J Radiol. 2001 Oct-Dec;2(4):210-5. doi: 10.3348/kjr.2001.2.4.210.

Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI.

Magn Reson Med. 1997 Mar;37(3):448-56. doi: 10.1002/mrm.1910370324.